Provided by Tiger Trade Technology Pte. Ltd.

Contineum Therapeutics, INC.

8.64
+0.07510.88%
Volume:1.29M
Turnover:10.92M
Market Cap:325.05M
PE:-5.02
High:8.94
Open:8.50
Low:8.10
Close:8.57
52wk High:17.79
52wk Low:8.10
Shares:37.62M
Float Shares:31.54M
Volume Ratio:1.13
T/O Rate:4.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7201
EPS(LYR):-2.1700
ROE:-28.01%
ROA:-19.15%
PB:1.36
PE(LYR):-3.98

Loading ...

Baird Downgrades Contineum Therapeutics to Neutral From Outperform, Price Target is $14

MT Newswires Live
·
Yesterday

Contineum Therapeutics, Inc. : Baird Cuts to Neutral Rating; Cuts Target Price to $14 from $19

THOMSON REUTERS
·
Yesterday

Contineum: Hold Rating Reiterated as ALOFT-IPF Validates Mechanism; Price Target Unchanged at $17 Pending Further PIPE-791 Data

TIPRANKS
·
Yesterday

Preview: Johnson & Johnson Earnings Expected to Decline in Q3

Reuters
·
Yesterday

Contineum: Buy Rating Reaffirmed as Bristol Data De-Risk PIPE-791, Price Target Slightly Trimmed to $28

TIPRANKS
·
Yesterday

Contineum Tumbles as Bristol's Partial Trial Win Raises Dose Doubts

Reuters
·
Oct 12

Jones sees greater room for Contineum’s PIPE-791 to differentiate

TIPRANKS
·
Oct 01

Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

TIPRANKS
·
Sep 30

Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from JonesTrading

TIPRANKS
·
Sep 30

Contineum Therapeutics Inc trading halted, volatility trading pause

TIPRANKS
·
Sep 30

NASDAQ Trade Halt Volatility Trading Pause at 03:50 Pm

Reuters
·
Sep 30

Contineum price target lowered to $17 from $18 at Morgan Stanley

TIPRANKS
·
Sep 28

Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTrading

TIPRANKS
·
Sep 28

RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM)

TIPRANKS
·
Sep 22

RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Sep 21

Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)

TIPRANKS
·
Sep 19

Shares of Contineum Down 9.9% After J&J-Partnered Depression Drug Fails Mid-Stage Trial

THOMSON REUTERS
·
Sep 16

Contineum Therapeutics Price Target Cut to $24.00/Share from $26.00 by Jones Trading

Dow Jones
·
Sep 15

LIVE Markets-Autumn in New York: Factory Expansion Slows, Input Prices at Multi-Year Highs - Empire State

Reuters
·
Sep 15

LIVE Markets-US Stock Indexes Swing Lower as Oil, Yields Jump

Reuters
·
Sep 15